Skip to content
Sign in

Company

Minghui Pharmaceutical

Open structure map

Structure of Minghui Pharmaceutical

Minghui Pharmaceutical

Company

3 connections
UpstreamSupply and dependency
PeersCompetition and partners
Relationship began2026
Minghui PharmaceuticalCompany · 3 connections
Layer 1

UpstreamSupply and dependency2

PeersCompetition and partners1

Place in the network

No. 15082 of 118934top 13%down 7912 places this week

3 direct links

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Minghui Pharmaceuticalagreement with →ASKA Pharmaceutical Co., Ltd.
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-04 14:30
      Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.
      View source
  • Stifelserves →Minghui Pharmaceutical
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-04 14:30
      Stifel is serving as exclusive financial advisor to Minghui
      View source
  • Fangda Partnersserves →Minghui Pharmaceutical
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-04 14:30
      Fangda Partners is serving as legal advisor.
      View source

Showing 1 to 3 of 3

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
servesStifel

Stifel is serving as exclusive financial advisor to Minghui

PR Newswire news releases · 2026-11-04 14:30

View evidence
  • CompanyPR Newswire news releases2026-11-04 14:30
    Stifel is serving as exclusive financial advisor to Minghui
    View source
FactEvidence 1

Fangda Partners is serving as legal advisor.

PR Newswire news releases · 2026-11-04 14:30

View evidence
  • CompanyPR Newswire news releases2026-11-04 14:30
    Fangda Partners is serving as legal advisor.
    View source
FactEvidence 1

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.

PR Newswire news releases · 2026-11-04 14:30

View evidence
  • CompanyPR Newswire news releases2026-11-04 14:30
    Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.
    View source
FactEvidence 1
upfront payment110 USD million

Minghui will receive an upfront payment of USD 110 million

PR Newswire news releases · 2026-11-04 14:30

View evidence
  • CompanyPR Newswire news releases2026-11-04 14:30
    Minghui will receive an upfront payment of USD 110 million
    View source
FactEvidence 1
tiered royalties on net sales in japan up tomid-30%

as well as tiered royalties up to mid-30% on net sales in Japan.

PR Newswire news releases · 2026-11-04 14:30

View evidence
  • CompanyPR Newswire news releases2026-11-04 14:30
    as well as tiered royalties up to mid-30% on net sales in Japan.
    View source

Showing 1 to 5 of 5

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance